Ge Long Hui·2026-01-23 22:33Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) has received a drug registration certificate from the Health Sciences Authority (HSA) of Singapore for its Pregabalin capsules, allowing the product to be marketed [1] Group 1: Product Approval and Indications - Pregabalin capsules are primarily used for the treatment of postherpetic neuralgia, diabetic peripheral neuropathy, fibromyalgia, spinal cord injury-related neuropathic pain, and as an adjunctive treatment for epilepsy [1] - The product's research and development were completed by Changzhou Pharmaceutical Factory in October 2019, and it received approval from the U.S. Food and Drug Administration in July 2021 [1] Group 2: Market Expansion and Investment - The drug has also been approved for market entry in Thailand by June 2025, indicating a strategic expansion into Southeast Asian markets [1] - The company has invested approximately RMB 2.19 million in research and development for the product's launch in Southeast Asia, which includes Thailand, Singapore, Malaysia, and the Philippines [1]